Trial Profile
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Asparaginase (Primary) ; Crisantaspase (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Folinic acid (Primary) ; Mercaptopurine (Primary) ; Pegaspargase (Primary) ; Prednisone (Primary) ; Ruxolitinib (Primary) ; Tioguanine (Primary) ; Vincristine (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 10 Jan 2024 Planned End Date changed from 28 Nov 2025 to 1 Feb 2026.
- 10 Jan 2024 Planned primary completion date changed from 28 Nov 2025 to 1 Feb 2026.
- 17 Feb 2023 Planned End Date changed from 29 Sep 2025 to 28 Nov 2025.